Table 3 Proportion of different types of sequelae among the 869 IMD survivors by factor from 2005–2020
Death within 30 days, n (%) | Total number of survivors | Hearing loss | Epilepsy | Learning disabilities* | Headache** | Visual defects and loss of vision | Abnormal involuntary movements | Other—the nervous and movement system | Arthritis*** | |
|---|---|---|---|---|---|---|---|---|---|---|
Proportion of IMD survivors with sequelae (%) | ||||||||||
Age group (years) | ||||||||||
0–5 | 11 (4%) | 281 | 6.8 | 3.9 | 5.3 | 1.4 | 4.3 | 1.1 | 0.4 | 1.4 |
6–15 | 2 (1%) | 142 | 9.2 | 6.3 | 5.6 | 2.8 | 2.8 | 0.7 | 0.7 | 0.7 |
16–25 | 14 (8%) | 179 | 8.4 | 5.6 | 2.2 | 6.7 | 2.2 | 1.7 | 1.1 | 0.6 |
26–65 | 10 (6%) | 163 | 7.4 | 8 | 2.5 | 4.9 | 1.8 | 3.1 | 3.7 | 3.1 |
66+ | 29 (28%) | 104 | 10.6 | 3.8 | 1.9 | 1 | 1 | 1.9 | ||
Serogroup^ | ||||||||||
B | 26 (7%) | 379 | 8.7 | 5.8 | 4.2 | 4 | 3.4 | 1.1 | 1.3 | 0.8 |
C | 20 (9%) | 232 | 10.8 | 4.3 | 3.9 | 2.6 | 3 | 1.7 | 1.3 | 1.7 |
W | 10 (14%) | 71 | 4.2 | 2.8 | 1.4 | 2.8 | 1.4 | 2.8 | ||
Y | 6 (11%) | 54 | 3.7 | 5.6 | 5.6 | 1.9 | 1.9 | 1.9 | ||
Other | 4 (3%) | 131 | 6.1 | 6.9 | 4.6 | 3.8 | 1.5 | 2.3 | 2.3 | 0.8 |
Clinical presentation | ||||||||||
Meningitis only | 11 (3%) | 315 | 9.8 | 6.7 | 2.2 | 4.8 | 2.2 | 1.3 | 2.2 | 0.6 |
Meningitis and septicaemia | 27 (11%) | 245 | 9 | 6.1 | 6.5 | 2 | 4.1 | 2 | 1.6 | 2 |
Septicaemia only | 26 (9%) | 285 | 5.6 | 3.9 | 2.8 | 3.5 | 2.1 | 1.4 | 0.4 | 0.7 |
Other invasive disease | 2 (8%) | 24 | 8.3 | 4.2 | 8.3 | |||||
Total | 66 (8%) | 869 | 8.2 | 5.4 | 3.6 | 3.5 | 2.8 | 1.5 | 1.4 | 1.3 |
Vascular disorders of the brain | Sequelae others | Mental retardation | Embolism, thrombosis, amputation, gangrene and skin necrosis | (CNS—abnormal US) | Hydrocephalus | Palsy**** | Walking difficulties and mobility disorders | Rehabilitation***** | |
|---|---|---|---|---|---|---|---|---|---|
Proportion of IMD survivors with sequelae (%) | |||||||||
Age group (years) | |||||||||
0–5 | 0.7 | 0.7 | 0.4 | 0.7 | |||||
6–15 | 1.4 | 0.7 | 0.7 | ||||||
16–25 | 1.7 | 1.1 | 1.1 | 1.1 | 0.6 | 2.8 | |||
26–65 | 1.2 | 0.6 | 0.6 | 0.6 | 0.6 | 4.9 | |||
66+ | 2.9 | 1 | 1 | 1 | 1 | 1.9 | 1 | 8.7 | |
Serogroup^ | |||||||||
B | 0.8 | 1.1 | 0.8 | 0.3 | 0.3 | 0.3 | 3.7 | ||
C | 1.7 | 1.3 | 1.3 | 0.9 | 0.9 | 0.4 | 0.4 | 2.2 | |
W | 1.4 | 4.2 | |||||||
Y | 1.9 | 1.9 | 1.9 | 1.9 | |||||
Other | 0.8 | 1.5 | |||||||
Clinical presentation | |||||||||
Meningitis only | 1.6 | 0.6 | 0.3 | 0.3 | 0.6 | 3.2 | |||
Meningitis and septicaemia | 1.2 | 2 | 1.2 | 0.4 | 0.4 | 0.4 | 1.6 | ||
Septicaemia only | 0.4 | 0.7 | 1.1 | 0.7 | 0.4 | 3.5 | |||
Other invasive disease | 4.2 | ||||||||
Total | 0.9 | 0.9 | 0.7 | 0.5 | (0.3) | 0.2 | 0.2 | 0.1 | 2.9 |